Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

July 27, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023

Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023

Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
May 6, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
May 4, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
April 27, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
April 26, 2023

Immunic to Participate in Investor and Scientific Conferences in May

Show per page